ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT

  • November 17, 2026

Share

Objective:

The presentation covers the efficacy and safety of atirmociclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a prior CDK4/6 inhibitor.

Approach:
  • Study: Phase 2 FOURLIGHT-1 study.
  • Treatment: Atirmociclib plus fulvestrant.
Interpretation:

The provided context identifies the study and treatment but does not report efficacy or safety results.

Limitations:
  • No study results, participant details, or methods beyond the phase and treatment are provided.
  • No source URL was supplied.

Original Source(s)

Related Content